Enliven Therapeutics, Inc. Common Stock
ELVNStock
$50.86+145.54%52W
Market Cap$3.63B
P/E—
Div yield—
Beta0.53
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)234.17%
Price vs S&P 500 (4W)24.34%
VGM Score80.58
Market Capitalization$3.63B
Earnings Surprise History
Q1 26-0.38est. -0.47
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.25
4.25
4.25
4.29
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ELVNEnliven Therapeutics, Inc. Common Stock | — | — | A | $50.86 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Enliven Therapeutics is a clinical-stage biopharmaceutical company developing small molecule targeted therapies for cancer. Its pipeline includes ELVN-001, which targets BCR-ABL fusion in chronic myeloid leukemia, and ELVN-002, a HER2 inhibitor designed to address both wild-type and mutant forms of the protein.